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Abstract
Background
Phocomelia is an extremely rare congenital malformation that emerged as one extreme of a
range of defects resulting from in utero exposure to thalidomide. Individuals with thalido-
mide embryopathy (TE) have reported developing symptoms suggestive of peripheral ner-
vous system dysfunction in the mal-developed limbs in later life.
Methods
Case control study comparing TE subjects with upper limb anomalies and neuropathic
symptoms with healthy controls using standard neurophysiological testing. Other causes of
a peripheral neuropathy were excluded prior to assessment.
Results
Clinical examination of 17 subjects with TE (aged 50.4±1.3 [mean±standard deviation]
years, 10 females) and 17 controls (37.9±9.0 years; 8 females) demonstrated features of
upper limb compressive neuropathy in three-quarters of subjects. Additionally there were
examination findings suggestive of mild sensory neuropathy in the lower limbs (n = 1), L5
radiculopathic sensory impairment (n = 1) and cervical myelopathy (n = 1). In TE there were
electrophysiological changes consistent with a median large fibre neuropathic abnormality
(mean compound muscle action potential difference -6.3 mV ([-9.3, -3.3], p = 0.0002) ([95%
CI], p-value)) and reduced sympathetic skin response amplitudes (-0.8 mV ([-1.5, -0.2], p =
0.0089)) in the affected upper limbs. In the lower limbs there was evidence of sural nerve
dysfunction (sensory nerve action potential -5.8 μV ([-10.7, -0.8], p = 0.0232)) and impaired
warm perception thresholds (+3.0°C ([0.6, 5.4], p = 0.0169)).
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Conclusions
We found a range of clinical features relevant to individuals with TE beyond upper limb com-
pressive neuropathies supporting the need for a detailed neurological examination to
exclude other treatable pathologies. The electrophysiological evidence of large and small
fibre axonal nerve dysfunction in symptomatic and asymptomatic limbs may be a result of
the original insult and merits further investigation.
Introduction
Phocomelia is a congenital malformation in which the proximal portions of the extremities are
poorly developed or absent and the hands and feet are attached directly to the trunk or by
means of a poorly formed bone [1]. It is extremely rare but emerged as a devastating side effect
and one of a range of limb defects in newborn children [2–5] exposed to the drug thalidomide
in utero. In contrast to many teratogenic drug side effects there was no dose response relation-
ship but its impact markedly time dependent acting between 20 and 36 gestational days in
utero [6–7], however even a single tablet at the appropriate time could result in the full blown
condition. This led to its withdrawal from use in humans in 1962. Thalidomide is now used
only in particular conditions where its side effects are a distal, axonal, symmetrical, predomi-
nantly sensory [8], dose-dependent [9–10] peripheral neuropathy [11–12].
Individuals born with thalidomide embryopathy (TE) have reported symptoms that may be
attributable to peripheral nervous system (PNS) dysfunction in the maldeveloped limbs in later
life [13, 14] and it has been hypothesized that “late onset neuropathy in thalidomiders will be
recognized as a sensory equivalent of post-polio syndrome” [15]. We set out to determine
whether there was any evidence of peripheral nerve dysfunction in subjects with TE limb
anomalies and neurological symptoms in the upper limbs. In contrast to a previous study [14]
we systematically investigated large and small somatic and sympathetic nerve function not
only in the symptomatic maldeveloped upper limbs, but also in the largely asymptomatic lower
limbs to ascertain whether there was any electrophysiological evidence of a more generalized
neuropathic dysfunction.
Materials and Methods
Ethics statement
This case control study was ethically approved by the East Central London Research Ethics
Committee (REC: 10/H0721/61).
Subjects
Subjects with maldeveloped upper limbs were identified by the Thalidomide Trust’s Health
Link Register on the basis of their confirmed exposure to thalidomide in utero, upper limb
anomalies, and clinical features suggestive of neuropathy in the upper limbs. Other causes of
peripheral neuropathy were excluded including diabetes, vitamin B12 deficiency, vasculitis,
and paraproteins. Further exclusion criteria included prior diagnosis of cervical myelopathy or
major anatomical anomalies making assessment impossible and inability to complete assess-
ment. Healthy volunteers were identified from the Neurosciences department or were carers/
friends attending with the subject. All subjects gave written informed consent and examina-
tions took place between April 2011 and October 2014.
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Clinical and neurophysiological assessment
Subjects underwent a full neurological examination (OM) and clinical neurophysiological
evaluation (AN). Assessment was limited in TE individuals due to anatomical abnormalities
and/or tolerance of the tests. Nerve conduction studies (NCS) were performed (Medtronic
Keypoint v5.06) on the upper (median [motor and sensory], ulnar [motor and sensory] and
superficial radial [sensory]) and lower limb (peroneal [motor], tibial [motor], sural [sensory]
and soleus H-Reflex). Median nerve compound muscle action potential (CMAP), when
obtainable, was recorded from a thenar eminence muscle. Needle Electromyography (EMG)
of one upper limb, usually limited, and/or lower limb proximal and distal muscles was per-
formed. Sympathetic skin response (SSR) was elicited by single pulse electrical stimuli from
palmar and plantar sites. Thermal threshold testing (TTT: Senselab-Thermotest Modular Sen-
sory Analyser, 25 x 50 mm thermode) to cool and warm sensation, cold and heat pain thresh-
olds was assessed in the distal upper and lower limbs. TTT was performed using the method
of limits: three successive stimuli were given decreasing or increasing from a starting tempera-
ture of 32°C at a rate of 1°C/second. Subjects pressed a button or indicated to the examiner
when the specific modality was perceived. Any delay <1 second was considered not to affect
the measure of threshold as the rate of temperature change of the thermal probe was 1°C/
second.
Statistical analysis
In NCS, TTT and SSRs we averaged the measurements of right and left limbs in each subject,
where both results were available, and, if only one measure was available, that was used. NCS,
TTT and SSR values, expressed as mean±standard deviation (SD), were compared between
subjects and controls in Gaussian linear models adjusting for age and gender. Group differ-
ences are reported with 95% confidence intervals and p-values of t-tests in the described linear
models testing the null hypothesis of no group difference. Because of the exploratory nature of
the study no adjustments for multiple testing were carried out. All analyses were carried out
using SAS version 9.4. A sample size of 17 patients per group yields a power of at least 80%
comparing two independent means at a two-sided significance level of 5% as long as the true
difference is in excess of one standard deviation. The sample size / power calculation was car-
ried out using nQuery Advisor version 7.0.
Results
Clinical features and neurological symptoms in upper limb TE
Seventeen subjects (50.4±1.3 years; 10 females) with TE, upper limb anomalies and poten-
tially neuropathic symptoms had upper limb abnormalities ranging from minimal change of
an absent thumb and absent/or hypotrophic thenar eminence to double index, three or four
digits only in the hand. Forearm anomalies varied from total absence to a partial anomaly
but some subjects had a normal proximal upper limb. All subjects had normal appearing
lower limbs, but two had a reduction in leg length. Upper limb sensory symptoms included:
discomfort, numbness and pins and needles. Three subjects complained of numbness in
their feet despite clinically normal lower limbs. Chronic pain was reported by seven subjects;
in six affecting the upper limbs and one reported generalized pain. Seven subjects com-
plained of weakness in their upper limbs despite the predominant sensory symptoms. One
subject reported sweating dysfunction (hypohydrosis) in the hands and feet. Seventeen
healthy volunteers (37.9±9.0 years; 8 females) had no limb abnormalities or neurological
symptoms.
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Potentially treatable neurological damage is commonly associated with
upper limb symptoms in TE
Clinical examination of TE subjects showed features of upper limb compressive neuropathy
(median or cervical radiculopathy) in 15 of 17 individuals; further intervention was managed
locally. The lower limb clinical neurological examination was entirely normal in 14 subjects
despite three reporting numbness in the feet. In three, despite the lack of clinical symptoms,
there was clinical evidence of changes consistent with a mild sensory neuropathy (n = 1), L5
radiculopathic sensory impairment (n = 1) and cervical myelopathy (n = 1), the latter required
neurosurgical decompression.
Large fibre neuropathic abnormalities are present in the affected upper
limbs and sensory changes are present in the asymptomatic, clinically
unaffected lower limbs
The CMAP of the median nerve showed no evokable response in six TE subjects and in some a
response could only be obtained by stimulating at the axilla. The mean median CMAP ampli-
tude was significantly reduced in subjects compared with controls. The ulnar CMAP amplitude
and the amplitude of the median and ulnar sensory nerve action potential (SNAP) were not
significantly different in subjects compared with controls (Table 1). Entrapment of median
nerve at the distal segment (at the wrist) was seen in five subjects (bilaterally = 1, right = 2 and
left = 2). The superficial radial SNAP could not be assessed in twelve TE subjects (due to radial
aplasia) but it was not significantly different compared with controls. Sural nerve SNAPs were
recordable in the lower limb and the mean amplitude was significantly reduced in subjects,
compared with controls (Table 1). No entrapment mono-neuropathies were found in the lower
limbs and no needle EMG abnormalities were found.
Sympathetic skin responses were abnormal in the affected, symptomatic
upper limbs whereas thermal thresholds were abnormal in
asymptomatic lower limbs
The mean perception threshold for warm sensation was significantly increased in the clinically
normal lower limbs in subjects compared with controls. Perception threshold for cool sensa-
tion and cold and heat pain thresholds were similar between TE subjects and controls in the
upper and lower limbs. SSRs were present in the upper and lower limbs of TE subjects but the
mean SSR amplitude in the palms was significantly reduced in the TE subject group, when
compared with the controls. For the SSR amplitudes on the plantar surfaces, however, no dif-
ferences in TE subjects compared with the controls could be detected (Table 2).
Discussion
To the best of our knowledge, this is the first study systematically assessing the peripheral ner-
vous system in both the clinically affected upper limb but also the lower limbs in middle-aged
subjects born with TE. All had confirmed thalidomide exposure in utero, limb reduction
defects ranging from thumb hypoplasia to phocomelia of the upper limbs with sensory symp-
toms, and most had normal appearing lower limbs.
In this group we found a range of problems that raised important clinical considerations for
individuals with TE [14]. Three-quarters had features suggesting upper limb compressive neu-
ropathy but, electrophysiological abnormalities consistent with compressive CTS were only
found in 5 subjects. This discrepancy arises from the complex anatomy, making the typical
electrophysiological findings of CTS unhelpful. In three subjects, cervical radiculopathy was
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suspected clinically, despite atypical dermatomal and myotomal anatomy, and subsequently
confirmed on cervical magnetic resonance imaging. These findings support the need for a
detailed examination of subjects with TE and neurological symptoms to exclude other treatable
pathologies.
In the abnormal upper limbs, evidence of a motor large fibre dysfunction was documented.
SSR was also reduced in the palms, consistent with additional sudomotor (efferent cholinergic
Table 1. Nerve conduction studies of the upper and lower limbs in controls (C) and thalidomide embryopathy (TE) subjects.
Controls (n = 17) (mean
+/- SD)
Thalidomide Embryopathy (n = 17)
(mean +/- SD)
Difference TE—C* (95% CI,
p-value)
Upper Limbs
Median CMAP amplitude (mV) 10.2±3.5 2.8±2.1 -6.3 ([-9.3, -3.3], p = 0.0002)
Ulnar CMAP amplitude (mV) 10.4±3.0 7.7±3.9 -2.6 ([-6.2, 1.0], p = 0.1497)
Median SNAP amplitude (μV) 15.5±7.1 5.2±3.5 -4.8 ([-9.9, 0.2], p = 0.0593)
Ulnar SNAP amplitude (μV) 12.9±5.7 6.1±2.2 -3.5 ([-7.5, 0.5], p = 0.0845)
Superﬁcial radial SNAP amplitude (μV) [in a
subset of 9 pts]
27.2±9.9 14.6±7.3 -9.0 ([-18.8, 0.8], p = 0.0686)
Lower limbs
Peroneal CMAP amplitude (mV) 7.4±3.9 4.3±4.1 -2.8 ([-7.1, 1.5], p = 0.1936)
Tibial CMAP amplitude (mV) 8.1±4.6 3.4±2.5 -1.7 ([-5.3, 1.9], p = 0.3493)
Sural SNAP amplitude (μV) 17.6±6.1 8.4±3.9 -5.8 ([-10.7, -0.8], p = 0.0232)
Sural CV (m/s) 59.4±6.0 50.7±5.0 -8.0 ([-13.9, -2.1], p = 0.0094)
Soleus H reﬂex latency (msec) 28.7±2.1 30.3±2.4 0.5 ([-1.7, 2.7], p = 0.6647)
* Group differences adjusted for age and gender and are reported with 95% conﬁdence intervals and p-values of t-tests in the described linear models
testing the null hypothesis of no group difference.
doi:10.1371/journal.pone.0152902.t001
Table 2. Thermal thresholds and sympathetic skin responses in the upper and lower limbs in controls (C) and thalidomide embryopathy (TE)
subjects.
Controls (n = 17) (mean +/-
SD)
Thalidomide Embryopathy (n = 17) (mean
+/- SD)
Difference TE-C* (95% CI, p-
value)
Hands
Warm perception threshold (°C) 34.4±0.6 35.0±1.2 0.5 ([-0.4, 1.4], p = 0.3043)
Cold perception threshold (°C) 30.3±0.5 30.0±1.2 -0.5 ([-1.4, 0.3], p = 0.2029)
Heat pain perception threshold
(°C)
42.0±4.2 44.1±4.1 3.0 ([-1.2, 7.1], p = 0.1533)
Cold pain perception threshold
(°C)
19.1±6.7 17.4±5.5 -0.2 ([-6.7, 6.2], p = 0.9447)
Sympathetic skin response (mV) 1.8±0.7 1.1±0.5 -0.8 ([-1.5, -0.2], p = 0.0089)
Feet
Warm perception threshold (°C) 35.9±1.2 39.1±3.1 3.0 ([0.6, 5.4], p = 0.0169)
Cold perception threshold (°C) 29.4±1.3 28.2±2.5 -1.6 ([-3.8, 0.6], p = 0.1365)
Heat pain perception threshold
(°C)
43.8±3.5 43.3±9.0 2.6 ([-5.3, 10.5], p = 0.5102)
Cold pain perception threshold
(°C)
17.1±6.7 16.9±5.9 -4.5 ([-11.4, 2.5], p = 0.1989)
Sympathetic skin response (mV) 0.8±0.7 0.6±0.7 -0.3 ([-1.0, 0.4], p = 0.3962)
* Group differences adjusted for age and gender and are reported with 95% conﬁdence intervals and p-values of t-tests in the described linear models
testing the null hypothesis of no group difference.
doi:10.1371/journal.pone.0152902.t002
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fibre) dysfunction. Longitudinal shortening of the radial aspect in the upper limb and tibial
aspect in the lower limb have been seen in the abnormal limb of phocomelic subjects [15]. Con-
sistent with these observations our subjects had radial aspect abnormalities in the clinically
abnormal upper limb but they did not have tibial aspect abnormalities. However, in the pre-
dominantly, grossly anatomically normal lower limbs, the mean amplitude of the sural SNAP
was reduced. Furthermore, TTT showed that warm perception was significantly different in
the lower limb in TE subjects. These findings together suggest axonal nerve dysfunction affect-
ing not only sensory large fibers but also the small fibres. The exclusion of other potential
causes of peripheral neuropathy increases the possibility that the electrophysiological abnor-
malities could have resulted from thalidomide exposure in utero. At the present time, the
majority of TE subjects do not have clinical evidence (signs or symptoms) of a peripheral neu-
ropathy affecting the lower limbs. As such, it is currently unclear whether the electrophysiolog-
ical abnormalities found in the lower limbs have been present long term, whether these are
progressive in nature, and whether they will prove to represent a clinically important part of
the TE syndrome in future. Thalidomide exposure in adults in some work but not all has been
found to cause a dose-dependent peripheral neuropathy [10, 16]. In TE the damage is markedly
time dependent as opposed to being dose dependent [6–7]. As Thalidomide exposure in the TE
group was in utero, it is possible that the neuropathic changes demonstrated here may have
arisen from the embryonic pathobiological defects causing TE and are not likely to be a direct
effect of thalidomide exposure. However, whether this is clinically relevant can only be deter-
mined with a follow-up study to determine whether further neuropathic symptoms develop
and to look for evolution of the electrophysiological abnormalities.
Supporting Information
S1 Protocol. Evaluation of the peripheral nervous system in patients with thalidomide-
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